The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Association Between Antiretroviral Exposure and Renal Impairment Among HIV-Positive Persons With Normal Baseline Renal Function: the D:A:D Studya
Open accessAbstract
BACKGROUND: Several antiretroviral agents (ARVs) are associated with chronic renal impairment, but the extent of such adverse events among human immunodeficiency virus (HIV)-positive persons with initially normal renal function is unknown. METHODS: D:A:D study participants with an estimated glomerular filtration rate (eGFR) of ≥ 90 mL/min after 1 January 2004 were followed until they had a confirmed eGFR of ≤ 70 mL/min (the threshold below which we hypothesized that renal interventions may begin to occur) or ≤ 60 mL/min (a value indicative of moderately severe chronic kidney disease [CKD]) or until the last eGFR measurement during follow-up. An eGFR was considered confirmed if it was detected at 2 consecutive measurements ≥ 3 months apart. Predictors and eGFR-related ARV discontinuations were identified using Poisson regression. RESULTS: Of 22 603 persons, 468 (2.1%) experienced a confirmed eGFR of ≤ 70 mL/min (incidence rate, 4.78 cases/1000 person-years of follow-up [95% confidence interval {CI}, 4.35-5.22]) and 131 (0.6%) experienced CKD (incidence rate, 1.33 cases/1000 person-years of follow-up [95% CI, 1.10-1.56]) during a median follow-up duration of 4.5 years (interquartile range [IQR], 2.7-6.1 years). A current eGFR of 60-70 mL/min caused significantly higher rates of discontinuation of tenofovir (adjusted incidence rate ratio [aIRR], 1.72 [95% CI, 1.38-2.14]) but not other ARVs compared with a current eGFR of ≥ 90 mL/min. Cumulative tenofovir use (aIRR, 1.18/year [95% CI, 1.12-1.25]) and ritonavir-boosted atazanavir use (aIRR, 1.19/year [95% CI, 1.09-1.32]) were independent predictors of a confirmed eGFR of ≤ 70 but were not significant predictors of CKD whereas ritonavir-boosted lopinavir use was a significant predictor for both end points (aIRR, 1.11/year [95% CI, 1.05-1.17] and 1.22/year [95% CI, 1.16-1.28], respectively). Associations were unaffected by censoring for concomitant ARV use but diminished after discontinuation of these ARVs. CONCLUSIONS: Tenofovir, ritonavir-boosted atazanavir, and ritonavir-boosted lopinavir use were independent predictors of chronic renal impairment in HIV-positive persons without preexisting renal impairment. Increased tenofovir discontinuation rates with decreasing eGFR may have prevented further deteriorations. After discontinuation, the ARV-associated incidence rates decreased.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Levey, A. S., Coresh, J., Balk, E., Kausz, A. T., Levin, A., Steffes, M. W., Hogg, R. J., Perrone, R. D., Lau, J., & Eknoyan, G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-2-200307150-00013 · Cited by 4,615
Simplified calculation of body surface area
(1987) · New England Journal of Medicine · doi:10.1056/nejm198710223171717 · Cited by 3,238
HLA-B*5701 Screening for Hypersensitivity to Abacavir
Mallal, S., Phillips, E., Carosi, G., Molina, J.-M., Workman, C., Tomažič, J., Jägel-Guedes, E., Rugina, S., Kozyrev, O., Cid, J. F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706135 · Cited by 1,835
Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030218 · Cited by 1,678
Gallant, J. E. (2004) · JAMA · doi:10.1001/jama.292.2.191 · Cited by 1,341
The NEW ENGLAND JOURNAL of MEDICINE
Gelijns, A. C., Rosenberg, N., & Moskowitz, A. J. (2009) · Studies on Science and the Innovation Process · doi:10.1142/9789814273596_0013 · Cited by 980
Eriksen, B. O., & Ingebretsen, O. C. (2006) · Kidney International · doi:10.1038/sj.ki.5000058 · Cited by 576
Cooper, R. D., Wiebe, N., Smith, N., Keiser, P., Naicker, S., & Tonelli, M. (2010) · Clinical Infectious Diseases · doi:10.1086/655681 · Cited by 565
Association of tenofovir exposure with kidney disease risk in HIV infection
Scherzer, R., Estrella, M., Li, Y., Choi, A. I., Deeks, S. G., Grunfeld, C., & Shlipak, M. G. (2012) · AIDS · doi:10.1097/qad.0b013e328351f68f · Cited by 424
Mocroft, A., Kirk, O., Reiss, P., De Wit, S., Sedlacek, D., Beniowski, M., Gatell, J., Phillips, A. N., Ledergerber, B., & Lundgren, J. D. (2010) · AIDS · doi:10.1097/qad.0b013e328339fe53 · Cited by 406
Self-citationKarras, A., Lafaurie, M., Furco, A., Bourgarit, A., Droz, D., Sereni, D., Legendre, C., Martinez, F., & Molina, J. (2003) · Clinical Infectious Diseases · doi:10.1086/368314 · Cited by 361
Tenofovir-Associated Acute and Chronic Kidney Disease: A Case of Multiple Drug Interactions
Zimmermann, A. E., Pizzoferrato, T., Bedford, J., Morris, A., Hoffman, R., & Braden, G. (2006) · Clinical Infectious Diseases · doi:10.1086/499048 · Cited by 314
Gallant, J. E., Parish, M. A., Keruly, J. C., & Moore, R. D. (2005) · Clinical Infectious Diseases · doi:10.1086/428840 · Cited by 302
Goicoechea, M., Liu, S., Best, B., Sun, S., Jain, S., Kemper, C., Witt, M., Diamond, C., Haubrich, R., Louie, S., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/524061 · Cited by 299
Arribas, J. R., Pozniak, A. L., Gallant, J. E., DeJesus, E., Gazzard, B., Campo, R. E., Chen, S.-S., McColl, D., Holmes, C. B., Enejosa, J., et al. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31815acab8 · Cited by 235
Tenofovir Disoproxil Fumarate in Nucleoside-Resistant HIV-1 Infection: A Randomized Trial
Squires, K., Pozniak, A. L., Pierone, G., Steinhart, C. R., Berger, D., Bellos, N. C., Becker, S. L., Wulfsohn, M., Miller, M. D., Toole, J. J., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-5_part_1-200309020-00006 · Cited by 198
Izzedine, H., Hulot, J. S., Vittecoq, D., Gallant, J. E., Staszewski, S., Launay-Vacher, V., Cheng, A., Deray, G., & for the Study 903 Team (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh658 · Cited by 182
Tenofovir renal proximal tubular toxicity is regulated By OAT1 and MRP4 transporters
Kohler, J. J., Hosseini, S. H., Green, E., Abuin, A., Ludaway, T., Russ, R., Santoianni, R., & Lewis, W. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.48 · Cited by 159
Risk Factors for ESRD in HIV-Infected Individuals: Traditional and HIV-Related Factors
Jotwani, V., Li, Y., Grünfeld, C., Choi, A. I., & Shlipak, M. G. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.10.050 · Cited by 143
Rompay, K. K. A. V., Brignolo, L. L., Meyer, D. J., Jerome, C. P., Tarara, R. P., Spinner, A., Hamilton, M., Hirst, L. L., Bennett, D. R., Canfield, D. R., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1469-1487.2004 · Cited by 140
Rollot, F., Nazal, E.-M., Chauvelot‐Moachon, L., Kelaïdi, C., Daniel, N., Saba, M., Abad, S., & Blanche, P. (2003) · Clinical Infectious Diseases · doi:10.1086/379829 · Cited by 131
Dauchy, F., Lawson‐Ayayi, S., de la Faille, R., Bonnet, F., Rigothier, C., Mehsen, N., Miremont‐Salamé, G., Cazanave, C., Greib, C., Dabis, F., et al. (2011) · Kidney International · doi:10.1038/ki.2011.124 · Cited by 115
Self-citationRisk Factors of Chronic Kidney Disease in HIV-infected Patients
Flandre, P., Puglièse, P., Cuzin, L., Bagnis, C. I., Tack, I., Cabie, A., Poizot-Martin, I., Katlama, C., Brunet-François, C., Yazdanpanah, Y., et al. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09191010 · Cited by 103
Mitochondrial Tubulopathy in Tenofovir Disoproxil Fumarate-Treated Rats
Lebrecht, D., Venhoff, A. C., Kirschner, J., Wiech, T., Venhoff, N., & Walker, U. A. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181a666eb · Cited by 102
Hamada, Y., Nishijima, T., Watanabe, K., Komatsu, H., Tsukada, K., Teruya, K., Gatanaga, H., Kikuchi, Y., & Oka, S. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis621 · Cited by 92
Young, J., Schäfer, J., Fux, C. A., Furrer, H., Bernasconi, E., Vernazza, P., Calmy, A., Cavassini, M. L., Weber, R. K., Battegay, M., et al. (2012) · AIDS · doi:10.1097/qad.0b013e32834f337c · Cited by 89
Self-citationPrevalence and Factors Associated with Renal Dysfunction Among HIV-Infected Patients
Crum‐Cianflone, N. F., Ganesan, A., Teneza-Mora, N. C., Riddle, M., Medina, S., Barahona, I., & Brodine, S. K. (2010) · AIDS Patient Care and STDs · doi:10.1089/apc.2009.0326 · Cited by 88
Rockwood, N., Mandalia, S., Bower, M., Gazzard, B., & Nelson, M. R. (2011) · AIDS · doi:10.1097/qad.0b013e32834a1cd6 · Cited by 85
Chang, H. R., & Pella, P. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmc061892 · Cited by 82
Overton, E. T., Nurutdinova, D., Freeman, J., Seyfried, W., & Mondy, K. (2009) · HIV Medicine · doi:10.1111/j.1468-1293.2009.00693.x · Cited by 81
Acute interstitial nephritis associated with atazanavir, a new protease inhibitor
Brewster, U. C., & Perazella, M. A. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.07.017 · Cited by 79
Schmid, S., Opravil, M., Möddel, M., Huber, M., Pfammatter, R., Keusch, G., Ambühl, P. M., Wuthrich, R. P., Moch, H., & Varga, Z. (2007) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-007-0418-3 · Cited by 61
Ibrahim, F., Hamzah, L., Jones, R., Nitsch, D., Sabin, C. A., & Post, F. A. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.03.006 · Cited by 59
Self-citationAtazanavir crystal nephropathy
Izzedine, H., m’rad, M. B., Bardier–Dupas, A., Daudon, M., & Salmon, D. (2007) · AIDS · doi:10.1097/qad.0b013e3282f17503 · Cited by 58
de Menezes, A. M., Júnior, J. F. T., Real, L. H. G., Bay, M. B., Poeta, J., & Sprinz, E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026042 · Cited by 54
Journal of Postgraduate Medicine
Bavdekar, S., Gogtay, N., Muzumdar, D., Vaideeswar, P., Salvi, V., & Sarkar, M. (2007) · Journal of Postgraduate Medicine · doi:10.4103/0022-3859.33852 · Cited by 54
Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection
Wyatt, C. M., & Klotman, P. E. (2006) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.2.275 · Cited by 49
Albini, L., Cesana, B. M., Motta, D., Focà, E., Gotti, D., Calabresi, A., Izzo, I., Bellagamba, R., Fezza, R., Narciso, P., et al. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31823a6124 · Cited by 42
Lopinavir–ritonavir (Kaletra) and lithiasis: seven cases
Doco‐Lecompte, T., Garrec, A., Thomas, L., Tréchot, P., May, T., & Rabaud, C. (2004) · AIDS · doi:10.1097/00002030-200403050-00022 · Cited by 40
Acute tubular necrosis in a patient receiving tenofovir
Lee, J. C., & Marosok, R. D. (2003) · AIDS · doi:10.1097/00002030-200311210-00021 · Cited by 35
Race, Kidney Disease Progression, and Mortality Risk in HIV-Infected Persons
Alves, T. P., Hulgan, T., Wu, P., Sterling, T. R., Stinnette, S. E., Rebeiro, P. F., Vincz, A. J., Bruce, M. A., & Ikizler, T. A. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00520110 · Cited by 24
Cited by
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
The INSIGHT START Study Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506816 · Cited by 2,798
The end of AIDS: HIV infection as a chronic disease
Deeks, S. G., Lewin, S. R., & Havlir, D. V. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61809-7 · Cited by 2,063
Deeks, S. G., Overbaugh, J., Phillips, A., & Buchbinder, S. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.35 · Cited by 644
Self-citationLucas, G. M., Ross, M. J., Stock, P. G., Shlipak, M. G., Wyatt, C. M., Gupta, S. K., Atta, M. G., Wools-Kaloustian, K. K., Pham, P. A., Bruggeman, L. A., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu617 · Cited by 310
Self-citationHIV infection and cardiovascular disease
Hemkens, L. G., & Bucher, H. C. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht528 · Cited by 251
Metadata
- Authors
- Ryom, L., Mocroft, A., Kirk, O., Worm, S. W., Kamara, D. A., Reiss, P., Ross, M., Fux, C. A., Morlat, P., Moranne, O., Smith, C., Lundgren, J. D., on behalf of the D:A:D Study Group, Dabis, F., El-Sadr, W., Pradier, C., Reiss, P., Kirk, O., Weber, R., Law, M., Morfeldt, L., de Wit, S., Calvo, G., d'Arminio Monforte, A., Shortman, N., Butcher, D., Rode, R., Franquet, X., Powderly, W., Sabin, C. A., Phillips, A., Lundgren, J. D., Ryom, L., Sabin, C. A., Kamara, D. A., Smith, C., Tverland, J., Nielsen, J., Salbol Brandt, R., Rickenbach, M., Fanti, I., Krum, E., Hillebregt, M., Geffard, S., Sundstrom, A., Delforge, M., Fontas, E., Torres, F., McManus, H., Wright, S., Kjaer;, J., Sjol, A., Meidahl, P., Helweg-Larsen, J., Schmidt Iversen, J., Worm, S. W., Ross, M., Fux, C. A., Morlat, P., & Moranne, O.
- Venue
- Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-02-04
- Volume
- 207
- Issue
- 9
- Pages
- 1359-1369
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2149717057
- Cited by
- 301
- References
- 43
- FWCI
- 31.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.